The former leader of China’s Centre for Disease Control implies that an official investigation was carried out by Beijing into the Wuhan lab.
Genedrive PLC – NICE recommends CYP2C19 genotyping
Genedrive plc (AIM: GDR), a leading provider of point-of-care molecular diagnostics, has announced that the UK’s National Institute for Health and Care Excellence (NICE) is advising in a draft guideline
Genedrive PLC (AIM:GDR) Commence of roll out in Greater Manchester
Genedrive ® MT-RNR1 to commence roll out in Greater Manchester Project to follow NICE final recomendations scheduled for end of this month
According to the US Department of Energy, it is probable that Covid-19 originated from a laboratory leak.
According to the Wall Street Journal, a recently updated and classified 2021 US Department of Energy study, provided to senior American lawmakers and the White House, suggests that the virus
Genedrive PLC (AIM:GDR) AIHL test preliminary recommendation by NICE
Antibiotic Induced Hearing Loss test receives preliminary recommendation by NICE NICE enters public consultation phase of Early Value Assessment of the Genedrive® MT-RNR1 System
Genedrive PLC (AIM:GDR) US FDA pre-submission for Genedrive MT-RNR1 kit
Genedrive file US FDA Pre-Submission for the Genedrive ® MT-RNR1 Product Range
Genedrive PLC (AIM:GDR) NICE includes Genedrive CYP2C19-ID Kit in new Diagnostics Assessment Programme
genedrive plc (AIM: GDR), the near-patient molecular diagnostics company, announces that the UK’s National Institute for Health and Clinical Excellence (‘NICE’) has commenced an evaluation of CYP2C19 genotype testing for
Genedrive PLC (AIM:GDR) Point-of-Care COV19-ID Kit receives CTDA approval
genedrive plc (AIM: GDR), the near patient molecular diagnostics company, announces that the UK Medicines and Healthcare Products Regulatory Agency has granted a CTDA enabling the sale of the Genedrive®
Genedrive PLC (AIM:GDR) NICE issues Medtech Innovation Briefing
NICE issues Medtech Innovation Briefing on Genedrive ® MT-RNR1 Test
Genedrive® MT-RNR1 ID Kit Product – Video
World’s first point of care genetic test used to influence neonatal management in an acute setting and reduce aminoglycoside-induced hearing loss​​
Genedrive PLC (AIM:GDR) First NHS Deployments of Genedrive System for AIHL
First NHS Deployments of the Genedrive® System for Antibiotic Induced Hearing Loss